Clinical trial NCT04460326
Conditions: Type 2 Diabetes Treated With Insulin
Keywords: Fiasp Novolog Continuous glucose monitor (CGM) Hypoglycemia Hyperglycemia Hemoglobin A1c
Sponsor: Boston Medical Center
Start date: 2020-12-07; Completion date: 2023-05-27
Enrollment: 137 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
Hyperglycemia affects 30-40% of hospitalized patients. Despite the fact that basal/bolus insulin therapy has been demonstrated to improve glycemic control and clinical outcomes in patients, achieving good glucose control remains a challenge.

This study examines the effects of Fiasp (a faster acting insulin) on blood sugars after meals compared to another type of insulin known as Novolog. The study will be performed in patients with type 2 diabetes admitted to the hospital, who are not in the intensive care unit, and who are being seen by the inpatient diabetes consult team. Eligible participants will be treated with Fiasp or Novolog injected multiple times a day before meals and at bedtime, in addition to a once daily injection of insulin glargine as basal insulin. Which type of meal time insulin (Fiasp vs Novolog) the subject gets is decided by chance, like the flip of a coin. Insulin doses will be started and titrated based on a protocol. All the subjects will wear a blinded continuous glucose monitoring (CGM)) sensor placed in their arm which they will wear for 72 hours during the study. The glucose values from the CGM, collected during the time it is worn, will be downloaded and compared to assess the response to the two different types of insulins - Fiasp and Novolog. The goal is to determine if Fiasp works as well as or better than Novolog in controlling blood sugars, particularly after meals, in the subjects of the study.

Detailed description:

Arms: arm 1: Group 1 will receive daily basal insulin glargine with a scheduled bolus of meal insulin Novolog. Meal Novolog will be dosed at the time the subject starts to eat. If the premeal blood glucose (BG) is ≥ 150 mg/dL, additional Novolog will be administered based off the correctional scale at the same time as the prandial insulin. The dose of Novolog will be administered by the floor nurse as per usual standard of care. arm 2: Group 2 will receive basal insulin glargine as dosed in Group 1. Meal insulin Fiasp dosing will be calculated the same way as Novolog dosing. If the premeal BG is ≥ 150 mg/dL, additional Fiasp will be administered based off the correctional scale at the same time as the prandial insulin.
Interventions: intervention 1: Insulin glargine intervention 2: NovoLog intervention 3: Insulin Fiasp intervention 4: Standard carbohydrate diet
Intervention descriptions: intervention 1: Insulin glargine doses will be determined by calculating the total daily dose (TDD) of insulin and providing 50% of the TDD as follows: start at 0.5 units/kg/day and subtract 0.1 unit/kg/day for 70+ yrs of age, renal insufficiency, pancreatic deficiency and add 0.1 unit/kg/day if hemoglobin A1c in \>10% intervention 2: Novolog will be administered with each meal if premeal glucose is ≥ 150 mg/dL and at bedtime if glucose is ≥ 200 mg/dL by calculating an individualized insulin sensitivity factor for each subject per the following formula: 1500/total daily dose of insulin = sensitivity factor. intervention 3: Fiasp will be administered with each meal if premeal glucose is ≥ 150 mg/dL and at bedtime if glucose is ≥ 200 mg/dL by calculating an individualized insulin sensitivity factor for each subject per the following formula: 1500/total daily dose of insulin = sensitivity factor. intervention 4: Standard carbohydrate diet as per usual hospital care (75g with each meal)

Protocol documents:
Prot_SAP_000.pdf: 
 
 
11 August 2022 Version 11 
1 
Comparison of postprandial glycemic 
control in non-critically ill hospitalized 
patients with type 2 diabetes mellitus using 
Novolog vs. Fiasp insulin: a Randomized 
Controlled Open Label Trial 
 
INVESTIGATOR-SPONSORED STUDY PROPOSAL 
UNIVERSAL TRIAL NUMBER (UTN) U1111-1242-6973 
NCT04460326  
Date 11/11/2022 
IRB Approved version on 09/29/2022 
Statistical Analysis Plan see pages 27-28 
 
 
Section of Endocrinology, Diabetes, Nutrition and Weight Management 
Boston Medical Center 
720 Harrison Avenue 
Boston, MA 02118 
 
Correspondence to: 
 
Sara Alexanian MD 
Director, Inpatient Diabetes Program 
72 East Concord Street C3  
Boston, MA 02118 
Phone: 617-638-7470 
Fax:  617-414-3797 
Sara.alexanian@bmc.org 
 
 


 
 
11 August 2022 Version 11 
2 
Confidentiality Statement: The information contained in this document is the property of 
Boston Medical Center, and is provided to you in confidence as an investigator, potential 
investigator, sponsor or consultant, for review by you, your staff, and an applicable Institutional 
Review Board or Independent Ethics Committee.  
The information is only to be used by you in connection with authorized clinical study described 
in the protocol. You will not disclose any of the information to others without written 
authorization from Boston Medical Center, except to the extent necessary to obtain informed 
consent from those persons to whom the intervention may be administered. 
 
 
Study Personnel 
Principal Investigator 
Sara Alexanian, MD 
Boston Medical Center 
Email: sara.alexanian@bmc.org 
  
Sub-Investigators 
Devin Steenkamp, MD 
Boston Medical Center 
Email: devin.steenkamp@bmc.org  
 
Nicole Spartano, PhD 
Boston Medical Center 
Email: spartano@bu.edu  
 
Niyoti Reddy, MD 
Boston Medical Center 
Email: niyoti.reddy@bmc.org  
 
 
Key Study Personnel: 
Ashley McCarthy 
Boston Medical Center 
Email: ashley.mccarthy@bmc.org  
  
 
Zhihui Ju 
Boston Medical Center 
Email: zhihui.ju@bmc.org 
 
Astrid Atakov Castillo 
Boston Medical Center 
Email: astrid.atakovcastillo@bmc.org 
 


 
 
11 August 2022 Version 11 
3 
Synopsis 
Primary Objective 
The primary objective of this trial is to determine if Fiasp® (insulin aspart injection) 
provides non-inferior postprandial glucose control compared with NovoLog® (insulin 
aspart injection) in non-critically ill hospitalized patients with type 2 diabetes (T2DM). 
Glycemic outcomes will be assessed using a continuous glucose monitoring system 
[Dexcom G6 Pro Continuous Glucose Monitoring (CGM) System]. The primary outcome 
will be time spent in sensor glucose (SG) target range 100-180 mg/dL (both inclusive) in 
all of the 4 hour postprandial periods during the study.   
Secondary Objectives 
The secondary objectives of this study will assess whether our Fiasp® intervention is 
superior to NovoLog® in terms of postprandial glucose control (time spent in SG target 
range of 100-180 mg/dL in all of the 4 hour postprandial periods).  
We will also assess glycemic control during other time periods during the study, and 
examine differences in hyperglycemia and hypoglycemia between groups. We will also 
analyze glucose variability and differences in insulin dosing between groups. All glycemic 
outcomes will be assessed using data obtained from CGM.   
Secondary outcomes will include:   
1. Percentage of time spent in the glycemic target range of 100-180 mg/dL (both 
inclusive) during the duration of the study. 
2. Percentage of time spent in the glycemic range of 70-140 mg/dL (both inclusive) in all 
of the 4 hour postprandial periods. 
3. Percentage of time spent in nocturnal glycemic target range 100-180 mg/dL (both 
inclusive) during the nocturnal period (00:01 AM to 05:59 AM, both inclusive) 
4. Percentage of time spent with hypoglycemia (<70 mg/dL, <54 mg/dL, and <40 mg/dL 
respectively) in all of the 4 hour postprandial periods, in the nocturnal period (00.01 
AM to 05:59 AM, both inclusive), and during the combined period of sensor wear 
during the study.   
5. Percentage of time spent with level 2 hyperglycemia (>240 mg/dL) in all of the 4 hour 
postprandial periods. 
6. Percentage of time spent with level 1 hyperglycemia (181-239 mg/dL, both inclusive) 
in all of the 4 hour postprandial periods. 
7. Mean SG glucose concentrations during the study. 
8. Glucose variability as measured by standard deviation (SD) of glucose and coefficient 
of variation (CV). 
9. Comparison of basal, prandial and correction insulin doses. 


 
 
11 August 2022 Version 11 
4 
10. Patient reported adverse effects from wearing a CGM and their perception of the 
experience of wearing a CGM while in the hospital. 
Study Duration 
24 months: 18 months for recruitment, 6 months for analysis.  
Study Design 
Open-label, 1:1 randomization without placebo control. 
Study Population 
Inclusion criteria: 
1. English-speaking or Spanish-speaking 
2. Males and female adult subjects admitted to Boston Medical Center to a medical or 
surgical floor. 
3. Age ≥ 21 and < 80 years. 
4. Diagnosed with type 2 diabetes at least 180 days prior to screening. 
5. Hyperglycemia during admission, as defined by a point of care and/or venous blood 
glucose ≥ 140 mg/dL.   
6. Prior to admission subjects must be using one of the following for outpatient diabetes 
management:  
a. Insulin 
b. ≥ 2 oral/injectable agents 
c. One oral/injectable agent with a HbA1c of ≥ 8% within 3 months of enrollment.  
7. Patients who are expected to remain hospitalized for a minimum of 48 hours following 
CGM sensor placement. 
8. BMI <45 kg/m2.  
9. Subjects must have insulin glargine dosing planned at bedtime for the duration of the 
study period. Morning and afternoon dosing of insulin glargine are exclusionary. 
Exclusion criteria: 
1. Patients with a history of type 1 diabetes or late-onset autoimmune diabetes (LADA). 
2. Currently on glucocorticoids OR plan for treatment with glucocorticoids within the next 
72 hours. 
3. Female patients who are pregnant (tested during hospitalization or screening) or 
breast-feeding during the hospitalization. 
4. Patients admitted with the following conditions: diabetic ketoacidosis, hyperosmolar 
hyperglycemic state, solid organ transplantation, or coronary artery bypass surgery. 


 
 
11 August 2022 Version 11 
5 
5. Prior diagnosis of gastroparesis or cirrhosis. 
6. Acute or chronic kidney disease with a serum creatinine of ≥ 2 mg/dL at the time of 
screening. 
7. Clinically significant nausea and/or vomiting or unable to consume more than 30 
grams of carbohydrate at each meal. 
8. Patients expected to receive nothing by mouth (NPO) for >24 hours.  
9. Use of continuous or intermittent enteral feeding or parenteral nutrition.   
10. Patients receiving > 1 gram every 6 hours of acetaminophen (maximum dose of 
acetaminophen) and/or hydroxyurea during the hospitalization.    
11. Any psychiatric condition rendering the subject unable to provide informed consent. 
12. Patients currently incarcerated. 
13. Patients using >1 unit/kg/day of insulin prior to admission. 
14. Insulin pump usage within the 2 weeks prior to or during admission.  
15. Patients currently using real-time continuous glucose monitoring (CGM) or personal 
flash glucose monitoring (FGM). 
16. Patients with a history of an allergy to any of the types of insulin or one of the 
excipients in the insulin used in the study. 
17. Patients who have tested positive for SARS-CoV-2 (severe acute respiratory 
syndrome coronavirus 2) in the past 30 days OR there is an ongoing clinical suspicion 
for COVID-19 infection. 
Number of Participants 
210 
Number of Study Sites 
Single site — Boston Medical Center 
Primary Outcome Variables 
All sensor glucose (SG) values collected by CGM during all of the 4 hour postprandial 
periods. 
Secondary and Exploratory Outcome Variables 
All SG values collected by CGM during the hospital stay, analyzed as detailed above, and 
insulin doses given in each group.  Demographic information including age, sex, race, 
BMI, reason for hospitalization, creatinine, HbA1c and medications for diabetes prior to 
hospitalization.   
 
 


 
 
11 August 2022 Version 11 
6 
Abbreviations 
Abbreviation  
Explanation 
BG 
Blood glucose 
BMC 
BMI 
Boston Medical Center 
Body mass index  
BUMC 
CGM 
CRF 
CT 
CV 
DPP-4 inhibitor 
GLP-1 
HbA1c 
Boston University Medical Center 
Continuous glucose monitoring device 
Case report form 
Computerized tomography scan 
Coefficient of variation 
Dipeptidyl peptidase-4 inhibitor 
Glucagon-like peptide 1 
Hemoglobin A1c 
ICF 
ICU 
IDS 
IRB 
IV 
FBG 
FGM 
Informed consent form 
Intensive care unit 
Inpatient Diabetes Service 
Institutional Review Board 
Intravenous 
Fasting blood glucose 
Flash glucose monitoring device 
MRI 
NPO 
OHRP 
PD 
PK 
PI 
Magnetic resonance imaging 
Nothing by mouth 
Office on Human Research Protection 
Pharmacodynamics 
Pharmacokinetics 
Principle investigator 
PPBG 
SG 
Postprandial blood glucose 
Sensor glucose 
SGLT2-i 
Sodium-glucose cotransporter-2 inhibitor 
SPSS 
TDD 
Statistical Package for the Social Sciences 
Total daily dose 
 
 
 
 
  
 


 
 
11 August 2022 Version 11 
7 
Table of Contents 
1 – 
Introduction ............................................................................................................ 10 
1.1. 
Introductory Statement ................................................................................................ 10 
2 – 
Background ............................................................................................................ 11 
2.1 
Background/scope of the problem ............................................................................... 11 
2.2 
Prior Experience ......................................................................................................... 11 
3 – 
Rationale/Significance ........................................................................................... 12 
3.1 
Problem Statement ..................................................................................................... 12 
3.2 
Purpose of Study/Potential Impact .............................................................................. 12 
3.2.1 
Potential Risks .....................................................................................................12 
3.2.2 
CGM risks ............................................................................................................13 
3.2.3 
Potential Benefits .................................................................................................13 
4 – 
Study Objectives .................................................................................................... 14 
4.1 
Hypothesis .................................................................................................................. 14 
4.2 
Primary Objective........................................................................................................ 14 
4.3 
Secondary Objectives ................................................................................................. 14 
5 – 
Study Design .......................................................................................................... 16 
5.1 
General Design Description ........................................................................................ 16 
5.1.1 
Study Date Range and Duration ..........................................................................18 
5.1.2 
Number of Study Sites .........................................................................................18 
5.2 
Primary Outcome Variables .................................................................................18 
5.2.1 
Secondary and Exploratory Outcome Variables ...................................................18 
5.3.1 
Number of Participants ........................................................................................18 
5.3.2 
Eligibility Criteria/Vulnerable Populations .............................................................18 
6 – 
Methods .................................................................................................................. 21 
6.1 
Method of Assignment/Randomization ........................................................................ 21 
6.2 
Assessments .............................................................................................................. 21 
6.2.1 
Safety/Pregnancy-related policy...........................................................................21 
6.2.1.2. Adverse Events Definition and Reporting ..................................................................22 


 
 
11 August 2022 Version 11 
8 
6.3 
Study Procedures ....................................................................................................... 24 
6.3.1 
Informed Consent ................................................................................................25 
6.3.2 
Screening ............................................................................................................25 
6.3.3 
Recruitment and Enrollment .................................................................................25 
6.3.4 
End of Study and Follow-up .................................................................................26 
6.3.5 
Removal of subjects .............................................................................................26 
6.3.6 
Statistical Design .................................................................................................27 
6.3.7 
Sample Size Considerations ................................................................................27 
6.3.7.1 
Primary Analyses .................................................................................................28 
6.3.7.2 
Secondary Objectives Analyses ...........................................................................28 
6.3.7.3 
Safety/Pregnancy-related policy...........................................................................28 
6.3.7.4 
Analysis of Subject Characteristics ......................................................................28 
6.3.7.5 
Interim Analysis ...................................................................................................28 
6.3.8 
Handling of Missing Data .....................................................................................28 
7 – 
Trial Administration ................................................................................................ 29 
7.1 
Ethical Considerations: Informed Consent/Assent and HIPAA Authorization .............. 29 
7.2 
Institutional Review Board (IRB) Review ..................................................................... 29 
7.3 
Subject Confidentiality ................................................................................................ 29 
7.4 
Deviations/Unanticipated Problems ............................................................................ 29 
7.5 
Data Collection ........................................................................................................... 29 
7.6 
Data Quality Assurance .............................................................................................. 30 
7.7 
Study Records ............................................................................................................ 30 
7.8 
Access to Source ........................................................................................................ 30 
7.9 
Data Storage/Security ................................................................................................. 30 
7.10 
Retention of Records .................................................................................................. 31 
7.11 
Study Monitoring ......................................................................................................... 31 
7.12 
Data Safety Monitoring Plan ....................................................................................... 31 
7.13 
Study Modification....................................................................................................... 32 
7.14 
Study Discontinuation ................................................................................................. 32 
7.15 
Study Completion ....................................................................................................... 32 


 
 
11 August 2022 Version 11 
9 
7.16 
Conflict of Interest Policy............................................................................................. 32 
7.17 
Funding Source .......................................................................................................... 32 
7.18 
Publication Plan .......................................................................................................... 32 
Appendix 1. Insulin initiation protocol ............................................................................ 34 
Appendix 2. Insulin Titration protocol ............................................................................. 35 
Appendix 3. Prescreening form ....................................................................................... 36 
Appendix 4. Patient Reported Outcome (PRO) Questionnaire ...................................... 37 
References ........................................................................................................................ 40 
 
 
 
 
 


 
 
11 August 2022 Version 11 
10 
1 – Introduction 
1.1. 
Introductory Statement 
This document is a protocol for a human research study to be conducted according to 
applicable government regulations and institutional research policies and procedures.  
 
 


 
 
11 August 2022 Version 11 
11 
2 – Background 
2.1 
Background/scope of the problem 
Hyperglycemia in hospitalized patients is associated with worse patient outcomes, including 
higher rates of infection, increase in morbidity, longer length of stay, and increased mortality (1, 
2).  Thus it is advised that blood sugar levels be maintained between 100-180 mg/dL in non-
critically ill patients (2).  Treatment with a regimen of basal, bolus and correction insulin is the 
recommended standard of care to manage inpatient hyperglycemia (3).  Insulin doses are 
calculated based on the weight of the patient and other clinical factors to derive a total daily 
insulin dose (TDD). This dose is then divided into 50% basal insulin, and the remaining 50% is 
divided into 3 and given prior to each of 3 meals per day in patients consuming meals (2, 3).  
Despite this standard, management of hyperglycemia in hospitalized patients remains a 
challenge, with many patients experiencing hyper or hypoglycemia (4).   
One challenge in managing diabetes with insulin replacement therapy is the relatively slow 
onset of action of rapid-acting insulin analogs such as NovoLog® (insulin aspart) or Humalog® 
(insulin lispro) compared with endogenous insulin secreted in response to carbohydrate 
consumption. This can lead to an excessive rise in blood glucose after meals.  Fiasp® (insulin 
aspart) is a formulation of insulin aspart with the addition of vitamin B3 (Niacinamide) and an 
amino acid (L-Arginine). It is a faster-acting insulin which has been shown to better control the 
early rise in blood glucose (BG) levels after consuming carbohydrates in the outpatient setting 
(5, 6).  Here we propose to compare postprandial BG control using a continuous glucose 
monitor in hospitalized patients receiving either NovoLog® or Fiasp®.   
2.2 
Prior Experience 
At Boston Medical Center (BMC), basal/bolus insulin therapy has been the standard of care for 
more than a decade.  As per recognized standard of care, we use tailored electronic orders to 
initiate and adjust insulin therapy in hospitalized patients.  All nurses are trained in the correct 
administration of basal, bolus and correction insulin.  Insulin is dosed based on the calculated 
TDD as above and adjusted based on BG response.  Providers order a standard amount of 
carbohydrates for patients with diabetes, most commonly 75 grams per meal.  A staff dietitian 
reviews the carbohydrate content of meals in the kitchen.   
Since 2006 we have had a dedicated Inpatient Diabetes Service, consisting of an 
endocrinologist, an endocrinology fellow, and diabetes nurse practitioners who see patients in 
consultation and assist in the management of hyperglycemia.  Our consult service typically 
manages the diabetes of 25-30 inpatients per day, with about 6 new consults per day.  Dr. Sara 
Alexanian, the principal investigator (PI) of this protocol, is the Director of the Inpatient Diabetes 
Service at BMC, which is the primary academic teaching hospital of Boston University School of 
Medicine. Dr. Alexanian is also the Quality lead in the Endocrinology Section at Boston 
University School of Medicine. The sub-investigator Dr. Steenkamp is the Director of Clinical 
Diabetes at BMC and is a current investigator in various diabetes clinical trials including trials 
investigating insulin, FGM and non-insulin diabetes pharmacotherapies in both type 1 and type 
2 diabetes. He has a particular interest in the use of technology in the management of diabetes.  
In 2015, 2 of the 3 investigators (Alexanian and Steenkamp) participated in a multi-center 
randomized controlled trial comparing basal/bolus insulin therapy to treatment with an oral DPP-
4 inhibitor in hospitalized patients.  We successfully recruited 70 patients over the course of the 


 
 
11 August 2022 Version 11 
12 
study, which was recently published in 2018 (7). Nicole Spartano, PhD, is a Research Assistant 
Professor in the Endocrinology Section with expertise in continuous data collection and analysis 
methods. She is working with Dr. Steenkamp on a research project investigating the 
effectiveness of a continuous glucose monitoring intervention in the primary care setting 
leveraging electronic (e)-consultation with endocrinologists. Dr. Spartano also serves as PI on 
grants from the American Heart Association and Alzheimer’s Association with recent 
publications in the JAMA Network, BMJ, Neurology, and Circulation.  
3 – Rationale/Significance 
3.1 
Problem Statement 
Hyperglycemia affects 30-40% of hospitalized patients (8, 9). Despite the fact that basal/bolus 
insulin therapy has been demonstrated to improve glycemic control and clinical outcomes in 
patients (10, 11), achieving good glucose control remains a challenge. Bolus insulin in a 
hospitalized patient is usually a rapid-acting insulin analog such as Humalog® or NovoLog®. 
The relatively slow onset of action of a rapid-acting insulin analog compared to endogenous 
insulin secretion can lead to an excessive rise in blood glucose after meals. Hyperglycemia in 
hospitalized patients is associated with worse patient outcomes, including higher rates of 
infection, increase in morbidity, longer length of stay, and increased mortality (1, 2).  
3.2 
Purpose of Study/Potential Impact 
The purpose of this study is to compare the standard practice of dosing rapid-acting analog 
NovoLog® vs Fiasp® at the time of a standardized carbohydrate meal in hospitalized patients.  
If Fiasp® is shown to improve postprandial glycemic control, and in particular reduce 
hypoglycemia in the postprandial period, this could potentially have wide-ranging impacts on the 
management of all hospitalized patients with hyperglycemia.   
3.2.1 Potential Risks 
The potential risks of the study are similar to risks that would be incurred with usual treatment 
with basal/bolus insulin in the hospital.  This includes both hyperglycemia and hypoglycemia, 
potential allergic reactions to insulin, and pain or bruising at the site of insulin injection.There is 
also the risk of a loss of confidentiality due to data collection.  
Blood samples will be taken during the course of the study as per usual hospital care. In 
addition, routine point of care blood glucose monitoring through fingersticks by use of 
standardized bedside glucometers will continue per standard inpatient protocols. There will be 
no additional blood samples required by the study protocol.    
Risks of CGM use include mild discomfort during sensor insertion, along with pain, redness, 
swelling, minor bleeding and minor infection at the sensor insertion site. Allergic reactions can 
develop in response to the sensor, the adhesive, and other parts of the CGM. There is a remote 
chance a sensor wire could break or detach and remain under the skin. Sterile broken or 
detached sensor wires usually don’t pose a significant clinical risk.  
Hypoglycemia:  The risk of hypoglycemia in insulin-treated non-ICU patients can range from 7-
23% in some studies (9, 12).  We anticipate that 10-20% of patients receiving insulin during the 
study may experience hypoglycemia.  The number of episodes of hypoglycemia and time spent 


 
 
11 August 2022 Version 11 
13 
in the range of hypoglycemia will be analyzed statistically from CGM-captured data.  
Hypoglycemia that requires treatment will be defined as a BG < 70 mg/dL.    
Hyperglycemia:  Quele et al (9) reported that 40% of patients receiving insulin during a hospital 
stay experienced more than 1 episode of hyperglycemia (BG >300 mg/dL).  For patients with ≥ 
2 blood glucose values >250 mg/dL at separate times of a single day, these subjects will be 
discontinued from the study insulin titration algorithm and insulin will be adjusted at the 
discretion of the study team per standard of care.   
Procedures for Protecting Against Risks 
Hyperglycemia and Hypoglycemia:  All glucose results obtained by the bedside glucose 
meter will be reviewed daily by the study team and insulin will be adjusted according to the 
study insulin titration protocol (Appendix 2).   
Hypoglycemia:  Subjects found to have hypoglycemia will be treated according to the hospital 
practice standard of care.    
For BG <70 mg/dL and patient is able to eat, give 16 g oral glucose, either juice or 
glucose tabs.  Recheck BG in 15 minutes. 
For BG <70 mg/dL with altered mental status and/or NPO give 12.5 g of IV dextrose.  
Recheck BG in 15 minutes, call MD if still <70 mg/dL.   
Insulin doses will be decreased as per study insulin titration protocol (Appendix 2) for a BG <70 
mg/dL.   
Hyperglycemia:  Subjects with 2 or more BG >250 mg/dL at separate times in a single day will 
be removed from the study insulin titration protocol and insulin doses will be titrated as per the 
discretion of the study team.   
Allergy:  Patients with a known history of allergy to NovoLog®, Fiasp® or insulin glargine used 
in the study will be excluded.   
Breach of Confidentiality: Only the PI, investigators and study personnel on this project will 
have access to the master code used to assign subject number. In addition, the investigators 
will be using password-protected computers and locked cabinets for data storage. 
3.2.2 CGM risks 
The sensor insertion site will be inspected by the research staff daily. If subjects develop an 
infection at the sensor insertion site or an allergic reaction develops in response to the sensor, 
the adhesive, and other parts of the CGM, it will be removed and subjects can anticipate that 
their symptoms will clear up within one week. Subjects can also request removal if they develop 
pain, redness, swelling or minor bleeding at the CGM insertion site. 
3.2.3 Potential Benefits 
Given the favorable postmeal pharmacokinetics of Fiasp®, this trial may demonstrate an 
alternative equivalent or superior way to dose meal insulin that mitigates hyperglycemia and/or 
hypoglycemia in hospitalized patients. If this is proven to be the case this would have landmark 
implications and likely shift national recommendations for inpatient diabetes care.   
 
 


 
 
11 August 2022 Version 11 
14 
4 –  Study Objectives 
4.1 
Hypothesis 
We hypothesize that giving Fiasp® will result in superior postprandial glucose control with less 
time spent in the hyperglycemic range as determined by 4 hour post-bolus CGM data, when 
compared with NovoLog® based on standardized carbohydrate intake. 
Pharmacokinetic and pharmacodynamic studies of Fiasp® vs NovoLog® showed significantly 
more rapid, earlier onset of the first appearance of Fiasp® in the circulation with approximately 
two times higher early insulin exposure, and 74-89% greater early glucose-lowering effect (5, 6, 
13). Therefore, Fiasp® has the potential for improving postprandial glycemic control in 
comparison to older rapid acting analogs in both patients with type 1 and type 2 DM.   
To the best of our knowledge, Fiasp® has not yet been evaluated in a hospitalized population 
with diabetes. CGM is the ideal tool to measure the effect of our intervention given the 
continuous measurement of glucose during a relatively short inpatient hospital admission and 
has the ability to accurately capture differences between groups. 
4.2 
Primary Objective 
The primary objective of this trial is to determine if Fiasp® (insulin aspart injection) provides 
non-inferior postprandial glucose control compared with NovoLog® (insulin aspart injection) in 
non-critically ill hospitalized patients with type 2 diabetes (T2DM). Glycemic outcomes will be 
assessed using a continuous glucose monitoring system [Dexcom G6 Pro Continuous Glucose 
Monitoring (CGM) System]. The primary outcome will be time spent in sensor glucose (SG) 
target range 100-180 mg/dL (both inclusive) in all of the 4 hour postprandial periods during the 
study.   
4.3 
Secondary Objectives 
The secondary objectives of this study will assess whether our Fiasp® intervention is superior to 
NovoLog® in terms of postprandial glucose control (time spent in SG target range of 100-180 
mg/dL in all of the 4 hour postprandial periods).  
We will also assess glycemic control during other time periods during the study, and examine 
differences in hyperglycemia and hypoglycemia between groups. We will also analyze glucose 
variability and differences in insulin dosing between groups. All glycemic outcomes will be 
assessed using data obtained from CGM.   
Secondary outcomes will include:   
1. Percentage of time spent in the glycemic target range of 100-180 mg/dL (both inclusive) 
during the duration of the study. 
2. Percentage of time spent in the glycemic range of 70-140 mg/dL (both inclusive) in all of the 
4 hour postprandial periods. 
3. Percentage of time spent in nocturnal glycemic target range 100-180 mg/dL (both inclusive) 
during the nocturnal period (00.01 AM to 05:59 AM, both inclusive) 


 
 
11 August 2022 Version 11 
15 
4. Percentage of time spent with hypoglycemia (<70 mg/dL, <54 mg/dL, and <40 mg/dL 
respectively) in all of the 4 hour postprandial periods, in the nocturnal period (00.01 AM to 
05:59 AM, both inclusive), and during the study.   
5. Percentage of time spent with level 2 hyperglycemia (>240 mg/dL) in all of the 4 hour 
postprandial periods. 
6. Percentage of time spent with level 1 hyperglycemia (181-239 mg/dL, both inclusive) in all of 
the 4 hour postprandial periods. 
7. Mean SG glucose concentrations during the study. 
8. Glucose variability as measured by standard deviation (SD) of glucose and coefficient of 
variation (CV). 
9. Comparison of basal, prandial and correction insulin doses between the two groups. 
10. Patient reported adverse effects from wearing a CGM and their perception of the experience 
of wearing a CGM while in the hospital. 
 


 
 
11 August 2022 Version 11 
16 
5 – Study Design 
5.1 
General Design Description 
This is an open-label trial without blinding. Eligible subjects will be randomized to 2 groups in a 
1:1 ratio to receive either Fiasp® or Novolog® at the start of the meal, which is our intervention. 
In addition to this, both groups will receive U100 insulin glargine dosed once daily for basal 
insulin, which is standard of care. Each subject will have a Dexcom G6 Pro CGM sensor 
inserted into the upper arm after signing consent and appropriate randomization by the study 
team.  Subjects will remain in the study for 72 hours (3 days) of active sensor wear time  in 
order to capture a minimum of 4 to a maximum of 6 insulin doses unless discharged from the 
hospital prior to that time, at which point the CGM sensor will be removed from the subject prior 
to discharge.  If the minimum insulin doses for study completion have not been captured within 
the first 72 hours of sensor wear, the sensor wear period may be extended up to an additional 
48 hours. 
In both groups insulin glargine doses will be determined by one of the following methods: 1) 
calculating the total daily dose of insulin and providing 50% of the TDD as follows:  
Determine initial TDD using baseline estimate and subtracting or adding for each risk factor: 
Baseline TDD estimate 
Start at 0.5 units/kg/day 
Age >70 years old 
-0.1 unit/kg/day 
If renal insufficiency 
-0.1 unit/kg/day 
If pancreatic deficiency 
-0.1 unit/kg/day 
If Hemoglobin A1c >10% 
+0.1 unit/kg/day 
FINAL TDD ESTIMATE 
= 
 
2) continue with patient current insulin dose 
The above algorithm is the standard approach to starting insulin in patients with hyperglycemia 
at BMC and is considered standard of care. Insulin glargine will be administered at bedtime to 
all study participants on the day of study entry (after signing informed consent). If a subject 
receives insulin glargine in the morning or afternoon, they will be excluded from the study. 
All insulin decisions will be directed by hospital bedside point of care glucose meter readings. 
The blood glucose data measured by the CGM will not be used to make insulin decisions. 
Correction insulin (Fiasp® or NovoLog®) will be administered with each meal if premeal glucose 
is ≥ 150 mg/dL and at bedtime if glucose is ≥ 200 mg/dL by calculating an individualized insulin 
sensitivity factor for each subject per the following formula: 1500/total daily dose of insulin = 
sensitivity factor.   
Group 1 will receive daily basal insulin glargine as per the calculation above, with a scheduled 
bolus of meal NovoLog®. As per the FDA approved labeling, NovoLog® should be given 
immediately (usually 5-10 minutes) prior to the start of a meal. Given that this is a hospital 
setting and insulin is administered by nursing, it is not practical to precisely time insulin 
injections and so meal NovoLog® will be dosed at the time the subject starts to eat (defined as: 
immediately prior to the first bite of the meal). NovoLog® doses will be determined using the 
above TDD calculation or continue with patient’s previous insulin dose, with half of the TDD 


 
 
11 August 2022 Version 11 
17 
being divided equally for each of the three meals.  The dose of NovoLog® will be administered 
by the floor nurse as per usual standard of care.  To prevent hypoglycemia, the subject will not 
be given prandial insulin if they do not eat, as per usual standard of care. As per usual hospital 
practice for prandial insulin, the dose of NovoLog® will be decreased by 2 units if the premeal 
blood sugar is between 70-100mg/dL. Additional correctional premeal NovoLog® will be added 
to the calculated prandial dose based on the ordered correctional (sliding) scale as appropriate.  
The bedtime NovoLog® correction scale (described above) will be given between 21:00 and 
22:00. 
Group 2 will similarly receive basal insulin glargine as dosed in Group 1. As per the FDA 
approved labeling, Fiasp® should be given at the start of or within 20 minutes of a meal. Given 
that this is a hospital setting and insulin is administered by nursing, it is not practical to precisely 
time insulin injections and so meal Fiasp® will be dosed at the time the subject starts to eat 
(defined as: immediately prior to the first bite of the meal). Meal Fiasp® dosing will be calculated 
the same way as NovoLog® dosing above. As per usual hospital practice for prandial insulin, 
the dose of Fiasp® will be decreased by 2 units if the premeal blood sugar is between 70-
100mg/dL. If the premeal BG is ≥ 150 mg/dL, additional Fiasp® will be administered based off 
the correctional scale at the same time as the prandial insulin. The bedtime correctional scale 
(described above) will be given between 21:00 and 22:00 utilizing Fiasp® insulin. 
See Appendix 1 for insulin initiation worksheet.   
Both groups will be ordered for a standard carbohydrate diet as per usual hospital practice (75g 
carbohydrate with each meal).   
Blood glucose levels will be monitored and insulin will be dosed using the standard hospital 
point-of-care glucose meters (Accucheck Inform II™ meter).  This is standard for use in the 
hospital to monitor glucose and adjust insulin.  The CGM data will not be visible to the subject, 
nurse, or study team in real time, but will be retrospectively downloaded to assess outcomes for 
the study.  Current BMC practice aligns with that of other hospitals in the United States, which 
may allow patients to wear continuous glucose monitors in the hospital, however does not use 
them to make insulin dosing decisions.  There have been some studies evaluating the accuracy 
and utility of CGM devices in non-critically ill patients (14, 15).  These studies have not found a 
significant difference in mean hospital glucose when comparing to data obtained by point-of-
care meters, but have shown a greater ability to detect hypoglycemia.   
On the day of enrollment and after obtaining informed consent, the Dexcom G6 Pro CGM 
sensor will be placed in the afternoon, with the insulin protocol to be started with basal insulin 
that evening at bedtime and the meal insulin dosing to begin the next morning. Each individual 
subject will have CGM data for a minimum of 4 and maximum of 6 meals during the study, 
unless the CGM sensor needs to be removed as described per protocol. 
Insulin doses will be titrated daily as per insulin titration protocol (Appendix 2).   
Subjects would continue in the study until discharge, or would be withdrawn if transferred to a 
higher acuity level of care, if nutrition method was changed, or after the subject has received 4-6 
meal doses within the 72 hours of active sensor wear time (3 days). If a subject does not 
receive the minimum 4  meal doses during the 72 hours, the sensor wear period may be 
extended up to an additional 48 hours in order to successfully complete the study.     


 
 
11 August 2022 Version 11 
18 
Subjects will be educated to avoid unscheduled eating to prevent potential hyperglycemic 
events at the time of enrollment and additionally if needed. 
 
 
5.1.1 Study Date Range and Duration 
From the date of first subject screening, we plan to consent 210 subjects, randomize 178 
subjects (89 per group) to achieve our target of 160 subjects (80 per group) who complete the 
study, over a period of 18 months. See section 6.7.3 for detailed power calculations. The active 
sensor wear time per subject will be 48-72 hours and maximum allowed active sensor wear time 
can be extended and additional 48 hours if needed to successfully complete the study. In the 
subsequent 6 months, the study team will analyze collected data and prepare for publication.  
5.1.2 Number of Study Sites 
Single site — Boston Medical Center 
5.2 
Primary Outcome Variables 
All SG values collected by CGM during the postprandial study period.   
5.2.1 Secondary and Exploratory Outcome Variables 
All SG values collected by CGM during the hospital stay, analyzed as detailed above in Section 
4.3 of the Study Objectives.  Insulin doses given in each group will be analyzed.  Demographic 
information including age, sex, race, BMI, reason for hospitalization, creatinine, HbA1c and 
medications prior to hospitalization.   
5.3 Study Population 
Participants with type 2 diabetes who are admitted to Boston Medical Center and who meet 
eligibility criteria. 
5.3.1 Number of Participants 
We anticipate that we will need to screen (consent) 210 patients to randomize 89 participants 
per group in order to achieve a sample size of 80 participants per group (expecting a 15% 
screen fail rate and a 10% rate of drop out or early hospital discharge). See section 6.7.3 for 
detailed power calcuations. 
5.3.2 Eligibility Criteria/Vulnerable Populations 
Participant eligibility should be reviewed and documented by an appropriately qualified member 
of the Investigator’s study team before subjects are included in the study. 
Participants must meet all of the following inclusion criteria to be eligible for enrollment into the 
study: 
Inclusion criteria: 
1. English-speaking or Spanish-speaking 


 
 
11 August 2022 Version 11 
19 
2. Males and female adult subjects admitted to Boston Medical Center to a medical or 
surgical floor. 
3. Age ≥21 and <80 years. 
4. Diagnosed with type 2 diabetes at least 180 days prior to screening. 
5. Hyperglycemia during admission, as defined by a point of care and/or venous blood 
glucose ≥ 140 mg/dL.   
6. Prior to admission subjects must be using one of the following for outpatient diabetes 
management:  
a. Insulin 
b. ≥ 2 oral/injectable agents  
c. One oral/injectable agent with a HbA1c of ≥ 8% within 3 months of enrollment.  
7. Patients who are expected to remain hospitalized for a minimum of 48 hours following 
CGM placement.  
8. BMI <45 kg/m2.  
9. Subjects must have insulin glargine dosing planned at bedtime for the duration of the 
study period. Morning and afternoon dosing of insulin glargine are exclusionary. 
Participant candidates must not be enrolled in the study if they meet any of the following criteria: 
Exclusion criteria: 
1. Patients with a history of type 1 diabetes or late-onset autoimmune diabetes (LADA). 
2. Currently on glucocorticoids OR plan for treatment with glucocorticoids within the next 72 
hours. 
3. Female patients who are pregnant (tested during hospitalization or screening) or breast-
feeding during the hospitalization. 
4. Patients admitted with the following conditions: diabetic ketoacidosis, hyperosmolar 
hyperglycemic state, solid organ transplantation, or coronary artery bypass surgery. 
5. Prior diagnosis of gastroparesis or cirrhosis. 
6. Acute or chronic kidney disease with a serum creatinine of ≥ 2 mg/dL at the time of 
screening. 
7. Clinically significant nausea and/or vomiting or unable to consume more than 30 grams 
of carbohydrate at each meal. 
8. Patients expected to receive nothing by mouth (NPO) for >24 hours.  
9. Use of continuous or intermittent enteral feeding or parenteral nutrition.   
10. Patients receiving > 1 gram every 6 hours of acetaminophen (maximum dose of 
acetaminophen) and/or hydroxyurea during the hospitalization.   
11. Any psychiatric condition rendering the subject unable to provide informed consent. 
12. Patients currently incarcerated. 


 
 
11 August 2022 Version 11 
20 
13. Patients using >1 unit/kg/day of insulin prior to admission. 
14. Insulin pump usage within the 2 weeks prior to or during admission.  
15. Patients currently using real-time continuous glucose monitoring (CGM) or personal 
flash glucose monitoring (FGM). 
16. Patients with a history of an allergy to any of the types of insulin or one of the excipients 
in the insulin used in the study. 
17. Patients who have tested positive for SARS-CoV-2 (severe acute respiratory syndrome 
coronavirus 2) in the past 30 days OR there is an ongoing clinical suspicion for COVID-
19 infection. 
Women of childbearing potential: A negative urine pregnancy test is required for all women of 
childbearing potential at screening, if one has not already been performed during the current 
hospitalization. Women in the postmenopausal state (defined as no regular menstrual bleeding 
for at least 1 year), women who have had their uterus removed (hysterectomy), both of their 
ovaries removed (bilateral oophorectomy), or who have undergone a bilateral tubal ligation are 
considered not of childbearing potential.  
 


 
 
11 August 2022 Version 11 
21 
6 – Methods 
6.1 
Method of Assignment/Randomization 
This is an open-label, 1:1 randomized trial.  Treatment assigned will be determined by the study 
team through computer-generated randomization.   
6.2 
Assessments 
The following assessments will be completed during the study: 
Medical History: Study staff will obtain a prior history of diabetes and outpatient diabetes 
treatment medications. For women of non-childbearing potential, the reason should be 
documented.  
Demographic/Medical information: Age, sex, BMI, vitals and reason for hospitalization will be 
obtained from the medical chart.  Patients will be asked their self-identified race/ethnicity (white, 
black, Hispanic/Latino, Asian, or other).  The most recent HbA1c if obtained during the index 
hospitalization or within 3 months prior to hospitalization will be collected from the medical chart.  
The serum creatinine at the time of randomization will be collected from the hospital record 
(note: serum creatinine is routinely obtained on all individuals admitted for inpatient care as part 
of the standard of care).   
Blood Glucose Values/use of CGM: For insulin adjustment and treatment and monitoring of 
hypoglycemia, the standard hospital point of care meter will be used.  At randomization a 
Dexcom G6 Pro CGM will be placed by the study team on the skin of the upper arm of the 
subject to collect blinded SG data during the study. The tiny sensor is under the skin and 
measures the interstitial glucose level, which is the glucose found in the fluid between the cells. 
The CGM device will be removed at the end of the study and the SG data from CGM will be 
used to assess glycemic outcomes.   
If at any time the CGM becomes dislodged, a new device will be placed by the study team as 
soon as possible.  If the patient must undergo a test during the study such as a CT scan or MRI 
where the CGM cannot be worn, the study team will remove the CGM prior to the test and place 
a new one as soon as possible immediately after the test.   
Patient Reported Outcome (PRO) questionnaire: Study subjects will be asked to complete a 
questionnaire at the completion of the study (after sensor removal and before discharge). This 
questionnaire will assess the subject’s perception of wearing a CGM device in the hospital and 
will also screen for adverse effects from wearing the CGM. 
6.2.1 Safety/Pregnancy-related policy 
Safety Measures: To ensure that the participant does not have any underlying health 
conditions, such as significant liver or kidney disease, the study team will review medical 
records from the hospitalization.   
Hypoglycemia: Subjects will be monitored with bedside glucose meters 4 times daily as per 
usual standard of care.  Subjects may have additional monitoring if hypoglycemia is noted, or if 
the patient complains of symptoms of hypoglycemia, or at the request of the treating physician.  
Hypoglycemia is treated as per standard of care at Boston Medical Center, with 16 grams of 
glucose given orally, followed by a repeat BG in 15 minutes for patients able to eat.  For patients 


 
 
11 August 2022 Version 11 
22 
not able to eat, 12.5 grams of dextrose will be administered from a 50% dextrose solution IV, 
followed by a repeat BG in 15 minutes.    
Pregnancy: A negative urine pregnancy test is required for all women of childbearing potential 
at screening.  The sponsor-investigator will report to Novo Nordisk any pregnancy occurring 
during the trial period. Reporting of pregnancy by sponsor-investigator will occur within the 
same timelines described for reporting of Adverse Events. Pregnancy complications will be 
recorded as adverse event(s). If the infant has a congenital anomaly/birth defect this must be 
reported and followed up as a serious adverse event. 
6.2.1.1  Storage and study Drug Accountability 
Study insulins will be stored per institutional research standard procedures and in accordance 
with US product label instructions at the Investigational Pharmacy Service at BMC.  Insulins 
used in the study will be administered as per usual standard of care by the hospital nursing staff 
and drug accountability will be performed by the study team and Investigational Pharmacy.   
6.2.1.2. Adverse Events Definition and Reporting 
Adverse Event: An Adverse Event (AE) is any undesirable medical event occurring to a subject 
in a clinical trial, whether or not related to the trial product(s). This includes events reported from 
the first trial related activity after the subject has signed the informed consent and until post 
treatment follow-up period as defined in the protocol, which in this study will be the last study 
visit. The following will not be recorded as AEs, if recorded as medical history/concomitant 
illness on the CRF at screening: 
• 
Pre-planned procedure, unless the condition for which the procedure was planned has 
worsened from the first trial related activity after the subject has signed the informed 
consent 
• 
Pre-existing conditions found as a result of screening procedures 
Clinical Laboratory Adverse Event: A clinical laboratory AE is any clinical laboratory 
abnormality regarded as clinically significant i.e. an abnormality that suggests a disease and/or 
organ toxicity and is of a severity, which requires active management, (i.e. change of dose, 
discontinuation of trial product, more frequent follow-up or diagnostic investigation). 
Serious Adverse Event (SAE): A serious AE is an experience that at any dose results in any of 
the following: 
• 
Death 
• 
A life-threatening* experience 
• 
In-patient hospitalisation or prolongation of existing hospitalization 
• 
A persistent or significant disability/incapacity 
• 
A congenital anomaly/birth defect 
• 
Important medical events that may not result in death, be life-threatening*, or require 
hospitalisation may be considered an SAE when, based upon appropriate medical 
judgement, they may jeopardise the subject and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition 
• 
Suspicion of transmission of infectious agents  


 
 
11 August 2022 Version 11 
23 
*The term life-threatening in the definition of SAE refers to an event in which the subject was at 
risk of death at the time of the event. It does not refer to an event which hypothetically might 
have caused death if it was more severe. 
Unanticipated Problem: An unanticipated problem is defined as an event, experience or 
outcome that meets all three of the following criteria: 
• 
is unexpected (in terms of nature, severity, or frequency) given (a) the research 
procedures that are described in the protocol-related documents (such as the IRB-
approved research protocol and informed consent document); and (b) the characteristics 
of the subject population being studied; AND 
• 
is related or possibly related to participation in the research (in this guidance document, 
possibly related means there is a reasonable possibility that the incident, experience, or 
outcome may have been caused by the procedures involved in the research); AND 
• 
suggests that the research places subjects or others at a greater risk of harm (including 
physical, psychological, economic, or social harm) than was previously known or 
recognized. 
Serious Adverse Drug Reaction (SADR): An adverse drug reaction (ADR) is an adverse 
event (AE) for which a causal relationship to the trial product is at least possible i.e. causal 
relationship is conceivable and cannot be dismissed. Serious adverse reaction (SAR): Adverse 
event which fulfils both the criteria for a Serious Adverse Event and the criteria for an Adverse 
Reaction. 
Suspected Unexpected Serious Adverse Reaction (SUSAR): An SAE which is unexpected 
and regarded as possibly or probably related to the trial/study product by the investigator.  
Medical Events of Special Interest (MESI): A MESI is (1) a medication error (e.g. wrong drug 
administration or wrong route of administration) or (2) a suspected transmission of an infectious 
agent via the product 
Precautions/Overdosage: Include information concerning precautions and procedures to be 
observed in the event of overdose by any trial product provided during the study. 
Non-Serious Adverse Event: A non-serious AE is any AE which does not fulfil the definition of 
an SAE. 
Severity Assessment Definitions: 
• 
Mild: Transient symptoms, no interference with the subject’s daily activities 
• 
Moderate: Marked symptoms, moderate interference with the subject’s daily activities 
• 
Severe: Considerable interference with the subject’s daily activities, unacceptable 
Relationship to study medication Assessment Definitions: 
• 
Probable: Good reasons and sufficient documentation to assume a causal relationship 
• 
Possible: A causal relationship is conceivable and cannot be dismissed 
• 
Unlikely: The event is most likely related to an etiology other than the trial product 
Outcome Categories and Definitions: 
• 
Recovered: Fully recovered or by medical or surgical treatment the condition has 
returned to the level observed at the first trial related activity after the subject signed the 
informed consent 


 
 
11 August 2022 Version 11 
24 
• 
Recovering: The condition is improving and the subject is expected to recover from the 
event. This term should only be used when the subject has completed the trial 
• 
Recovered with sequelae: As a result of the AE, the subject suffered persistent and 
significant disability/incapacity (e.g. became blind, deaf, paralysed). Any AE recovered 
with sequelae should be rated as an SAE 
• 
Not recovered 
• 
Fatal 
• 
Unknown 
Collection, Recording and Reporting of Adverse Events: All events meeting the definition of 
an adverse event must be collected and reported from the first trial related activity after the 
subject has signed the informed consent and until the end of the posttreatment follow-up period 
as stated in the protocol, which will be the day of the last study visit.  
At each contact with the participant, the investigator or study staff will seek information on 
adverse events by specific questioning and, as appropriate, by examination. Information on all 
adverse events should be recorded in the source document, and also in the appropriate adverse 
event form of the CRF. All clearly related signs, symptoms, and abnormal diagnostic procedures 
results should be recorded in the source document. All adverse events occurring during the 
study period must be recorded.  The information reported to the sponsor will include at a 
minimum the study name, patient identification (subject number, initials, sex, age), event and 
diagnosis if available, trial drug, reporter, causality, and outcome. 
Unanticpated Problems should be reported to the BUMC IRB within 7 days of the PI learning of 
event. Adverse Events that are not Unanticipated Problems should be submitted during the 
annual continuing review.  
All SAEs, SUSARs, and SADRs need to be recorded and reported to Novo Nordisk within 24 
hours of investigator’s knowledge of the SAE. The investigator must submit any updated SAE 
data to Novo Nordisk within 24 hours of it being available. 
Post-study Adverse Event: All unresolved adverse events should be followed by the study 
team until the events are resolved, the participant is lost to follow-up, or the adverse event is 
otherwise explained. In the rare circumstance that a subject has experienced an adverse event 
directly related to being in this study, which has not resolved by the time of discharge, the study 
team will contact the patient by telephone daily until the adverse event has resolved. We 
anticipate that the only adverse event related to the study that could persist by the time of 
discharge would be CGM related risks. Due to the nature of the study, no delayed toxicities or 
withdrawal effects are expected after a participant has discontinued participation in the study. 
Therefore, no collection of new safety information will be done after participant's discontinuation 
from the study. 
6.3 
Study Procedures 
Subjects eligible for study recruitment will have the nature, purpose, and risks of the study 
explained to them by the Investigator or their designee. They will be provided with a written copy 
of the informed consent form (ICF) for the study and given sufficient time to consider the study's 
implications before deciding to participate. Subjects agreeing to participate in the study will sign 
the ICF and be given a duplicate copy before undergoing any screening procedures. A unique 
ID number will be issued at the time of consent by the study team. 


 
 
11 August 2022 Version 11 
25 
• 
Informed consent must be obtained before any study related activity. 
• 
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. 
• 
The investigator or their designee will maintain a screening log to record details of all 
participants screened and to confirm eligibility or record reason for screen failure, as 
applicable. 
6.3.1 Informed Consent 
All eligible and willing subjects will be consented prior to any procedures being performed. 
Subjects will be given the opportunity prior to the consent process to read and review the 
consent form. During the informed consent process, a study staff member, who is also a 
physician, will review main areas of the study design, address all subject concerns, reinforce the 
study's commitment to the subject and reinforce the commitment needed from the subject to be 
in the study. Subjects will be allowed as much time as they need prior to signing the consent 
form. If the subject is limit- or non-reader, a “teach back” method will be used at consent to 
ensure the subject understand the study.  
6.3.2 Screening 
Pre-screening: Potentially eligible participants will be identified from the list of inpatients with 
diabetes in Epic.  Patients who meet the preliminary study criteria (determined by completion of 
the Pre-Screen Form, Appendix 3 by the research staff) will be approached to consent for the 
trial.  
Screening Visit: Participants will first be asked to give written, informed consent. A screening 
visit from the study team to the patient bedside will be completed to confirm subject eligibility. 
Assessments and procedures at the Screening Visit include: 
• 
Informed consent will be obtained from the patient 
• 
Medical history will be obtained from the hospital chart and will be reviewed with the 
patient 
• 
Antihyperglycemic therapy prior to hospitalization will be obtained from the hospital chart 
and will be reviewed with the patient 
• 
Medications currently being administered in the hospital (to review for exclusion criteria) 
will be obtained from the hospital chart 
• 
Demographics (self-reported and obtained from hospital chart) will be reviewed with the 
patient 
• 
Vitals and anthropometrics (height, weight, BMI) will be obtained from hospital chart 
• 
Laboratory tests available in medical record (HbA1c and serum creatinine) will be 
reviewed 
• 
Urine pregnancy test will be administered to women of child-bearing potential who have 
not had a pregnancy test in the current hospitalization. 
6.3.3 Recruitment and Enrollment 


 
 
11 August 2022 Version 11 
26 
Recruitment: Subjects will be recruited by reviewing the list of inpatients with diabetes from 
Epic. The study team will review the patient's sex, age, medical history, medications, ability to 
speak English or Spanish and BMI from Epic Systems Corporation (EPIC) medical records. 
Patients meeting the study criteria will be introduced to the study by a clinician who may also be 
an investigator. These patients will be screened in-person by the study team.   
Enrollment: Participants are enrolled in the study when they have signed the ICF.  Patients 
who enroll will receive $25 dollars per day of participation, with a maximum of $75 per subject. 
Payment will occur via ClinCard (a reloadable debit card), which subjects will receive after the 
consent process. After completion of participation, the study coordinator will add $25 to the card 
for each day of participation up to a maximum of $75. At the onset of the study, participants will 
be enrolled on 4 regular inpatient floors only (Menino building floors 6 East, 6 West, 7 East, 7 
West), but this will be expanded to all other regular med-surg inpatient floors and stepdowns 
after the recruitment of 10 participants OR two months from study onset (whichever occurs first).  
During the study: Please refer to section 5.1 General Design Description for a detailed review 
of what will happen once patients are recruited in the study. 
6.3.4 End of Study and Follow-up 
When participants have been in the study for three days the study will be completed.  At study 
completion, participants with complete a Patient Reported Outcome (PRO) Questionnaire 
(Appendix 4).  Patients may also be discontinued prior to 3 days if they withdraw consent, are 
transferred to a higher level of care, die during admission, are started on > 1 gram of 
acetaminophen and/or hydroxyurea by the primary medical/surgical team or are discharged 
from the hospital. 
6.3.5 Removal of subjects 
Every effort should be made to conduct all protocol-required procedures to complete the study. 
Participants may be removed from the study for the following reasons: 
• 
Withdrawal of Consent: Participant wishes to exercise the right to withdraw from the 
study as stated in the ICF (all participants reserve the right to withdraw from the study 
without prejudice). We will still use the data obtained up until the time of withdrawal. 
• 
Adverse Event: Participant experiences an adverse event that, in the investigator's 
opinion, necessitates withdrawal from the study. 
• 
Investigator Decision: Investigator feels it is in the participant's best interest to terminate 
participation for reasons other than an adverse event. 
• 
Protocol Violation: Participant is noncompliant with protocol procedures, violates study 
entry criteria, or starts an exclusionary concomitant medication. Examples of this 
include: started on > 1 gram of acetaminophen and/or hydroxyurea by the primary 
medical/surgical team while wearing the CGM sensor 
• 
Administrative Reason: The study sponsor or other regulatory authority discontinues the 
study protocol or the clinical study site discontinues participation. 
Any withdrawal must be fully documented in the participant's source records and recorded on 
the disposition page of the CRF. The documentation must include the reason for the withdrawal 


 
 
11 August 2022 Version 11 
27 
and details of any sequelae (followed until symptoms resolve or improve, as appropriate). 
Withdrawals due to an adverse event must be documented on both the disposition page and the 
adverse event page of the CRF. 
6.3.6 Statistical Design 
The design is a randomized, open-label study. In order to reduce bias we propose stratified 
randomization per ward, whereby separate randomization lists will be developed for each 
individual ward. 
The Dexcom G6 Pro CGM sensor will store four measurements per hour.  If each subject 
remains in the study after sensor placement for a minimum of 48 hours, each subject will have 
192 glucose measurements and a minimum of 4 postmeal periods of data.  We will discard data 
from the first 12 hours after sensor placement given concerns about data accuracy during this 
time period, leaving a minimum of 144 measurements/subject.  As the CGM will be placed the 
afternoon prior to starting the prandial insulin dosing, we anticipate that discarding the first 12 
hours of data will have minimal impact on the study.   
6.3.7 Sample Size Considerations 
Although our primary objective is to assess the non-inferiority of our intervention, we calculated 
power based on our secondary analysis in which we assess the superiority of our intervention 
because a much lower sample size is required for the non-inferiority analysis given our 
anticipated results.  
Powering non-inferiority of our primary outcome: Using a one-sided (alpha=0.025) power 
calculation, we estimate that we would need a sample size of 63 participants per group to have 
80% power to detect non-inferiority of Fiasp® compared to NovoLog® in postmeal time in 
glycemic range (100-180 mg/dl), assuming we set our non-inferiority margin at 5% less time in 
glycemic range and a standard deviation of 10%. A 5% non-inferiority margin was set according 
to an international consensus report stating that changing time in range by 5% increments 
would be clinically relevant. It is important to note that we have no true reference for a standard 
deviation of postmeal time in range for our study population, so we chose a conservative (higher 
than expected) standard deviation. These calculations are also conservative because they 
assume no hypotheses about superiority of Fiasp® (using sealedenvelope.com to calculate 
power).  
We also estimated requiring only 63 participants to have 80% power (alpha=0.05) to detect a 
2.5% greater time in glycemic range (superiority) for participants randomized to Fiasp®, 
compared to NovoLog® (with a 5% standard deviation of the outcome), however, we expect a 
greater change in percent time in range. 
We will be sufficiently powered for non-inferiority (and superiority) of our primary outcome 
because we have chosen to power our study in order to be able to execute our secondary 
analysis, described below. 
Powering for secondary analysis: We estimate that 80 participants per group will provide 
80% power (alpha=0.05, two sided) to detect a 20 mg/dL difference in mean 24 hour (day 2) 
glucose between groups, assuming a standard deviation for mean glucose of 45 mg/dL, which 
was reported previously in a study of inpatient prandial insulin dosing (16). Previous intervention 
studies using CGM have reported larger differences (treatment vs. control) for time in target 


 
 
11 August 2022 Version 11 
28 
glycemic range compared to differences in mean glucose (17), and we also expect larger 
differences (treatment vs. control) for glucose variability. Therefore, we expect to have greater 
power to detect differences in our primary outcome (percentage of time in the glycemic target 
range) because these measures have proved to be a sensitive measure of glycemic control 
which leverage the full granularity of CGM data (18, 19).   
We anticipate that we will need to screen 210 patients to randomize 89 participants per group in 
order to achieve a sample size of 80 participants per group (expecting a 15% screen fail rate 
and a 10% rate of drop out or early hospital discharge). 
6.3.7.1 Primary Analyses 
The percentage of time spent in various glycemic target range will be calculated as the number 
of measurements in each glycemic range divided by the total number of recorded 
measurements.  We will compare the percentage of time spent in range (100-180 mg/dL, both 
inclusive) in the postprandial period using Student t tests, among those randomized to 
NovoLog® vs. Fiasp®. Non-inferiority of Fiasp® can be confirmed if participants randomized to 
Fiasp® demonstrate <5% lower amount of time spent in glycemic target range compared to 
NovoLog®. 
6.3.7.2 Secondary Objectives Analyses 
We will compare percentage of time spent in other ranges of interest as detailed in the Study 
Objectives using Student t tests between NovoLog® vs. Fiasp® groups.  We will explore other 
demographic factors in modeling procedures (including age, sex, and BMI) using analysis of 
covariance.   
In additional sensitivity analysis, we will repeat all analysis using only data from the first three 
meals for each patient in order to partially account for differences in hospitalization duration.  
6.3.7.3  Safety/Pregnancy-related policy 
See Section 7.12 Data Safety Monitoring Plan. 
6.3.7.4 Analysis of Subject Characteristics 
Descriptive subject variables are age, sex, race, serum creatinine and HbA1C.  
6.3.7.5 Interim Analysis 
There is no planned interim analysis for this study. 
6.3.8 Handling of Missing Data 
We anticipate minimal time periods of missing sensor data due to insufficient device attachment 
or device removal.  These periods will be excluded from analysis. Only non-missing data will be 
analyzed.  
 
 
 


 
 
11 August 2022 Version 11 
29 
7 – Trial Administration 
7.1 
Ethical Considerations: Informed Consent/Assent and HIPAA Authorization 
Informed Consent: Study will be conducted in accordance with ICH GCP guidelines and 
Declaration of Helsinki.  Sponsor-investigator will comply with all applicable regulatory and legal 
requirements in obtaining and documenting the informed consent.  Sponsor-investigator will 
ensure that participants or their legally acceptable representative are clearly and fully informed 
about the purpose, potential risks and other critical issues regarding this clinical trial. 
The preparation of the ICF(s) used for this study is the responsibility of the PI and must include 
all elements required by applicable regulatory requirements. Prior to beginning the study, the 
ICF(s) will be approved by the IRB. The consent form(s) used will bear the IRB stamp on all 
pages. 
7.2 
Institutional Review Board (IRB) Review 
Before study initiation, the PI must have written and dated approval/favorable opinion from an 
IRB for the protocol, consent form/s, and any other written information provided to participants. 
The PI should also provide the IRB with product labeling. 
The PI will provide the IRB with reports, updates and any other information according to 
regulatory requirements or IRB procedures. 
7.3 
Subject Confidentiality 
Only the PI, investigators and study personnel on this project will have access to the master 
code. In addition, the investigators will be using password-protected computers and locked 
cabinets for document storage. 
7.4 
Deviations/Unanticipated Problems 
The study shall be conducted as described in this approved protocol. Deviations or changes to 
the protocol shall be made only after amendment approval/favorable opinion by the IRB, except 
where necessary to eliminate immediate hazard to study participants. Any significant deviation 
will be documented in the study team progress notes and reported to the IRB per regulations. 
If an amendment substantially alters the study design or increases potential risk for study 
participants, the Informed Consent should be revised and submitted to the IRB. Once the IRB 
has approved the revised Informed Consent, all study participants currently enrolled in the study 
must sign the amended consent, and the new consent will be used for all new participants prior 
to enrollment. 
7.5 
Data Collection 
The site will perform all data management activities, including the writing of a data management 
plan outlining the systems and procedures to be used. Data will be collected directly from study 
participants or their medical records after receiving written informed consent. Data will be 
collected onto paper source documents and then transcribed into the study database. Study 
data will be accessible to study staff who are approved to work on this protocol. 
Destruction of Identifiers: Paper participant records will be kept in a locked office and 
electronic study data will be stored in a computer database that will be password-protected and 


 
 
11 August 2022 Version 11 
30 
kept on the Endocrinology shared drive. A password-protected master code list will be created 
that links the subjects study number to the subjects’ identity. The office will be locked at all times 
when charts are not in use and will only be accessible to study staff. Coded data will be kept 
indefinitely after completion of the study.  
7.6 
Data Quality Assurance 
The study team is responsible for the data management of this trial including quality checking of 
the data. For data analysis, all data will be downloaded from the electronic databases and 
reformatted into SPSS data sets.  
7.7 
Study Records 
The investigator and their team will maintain adequate and accurate records that fully document 
the conduct of the study and enable study data to be verified. These documents should be 
classified into separate categories: (1) investigator's study file, and (2) participant clinical source 
documents. 
(1) The investigator's study file includes the original protocol, protocol amendments, official data 
capture forms and query forms, IRB approval with correspondence, approved informed consent 
form, staff curriculum vitae and authorization forms, and other appropriate documents and 
correspondence. 
(2) Participant clinical source documents include patient hospital/clinic records, physician's and 
nurse's notes, screening and enrollment log, etc. 
The investigator and their team is required to prepare and maintain adequate and accurate case 
histories for each participant involved in the study. Source documents and electronic records 
entered in the study database must be consistent with each other, and discrepancies explained. 
Corrections must be made by striking incorrect data with single line and entering correct 
information followed by authorized person's initials and date. 
7.8 
Access to Source 
Clinical study data will be reported (captured) by study site personnel on paper source 
documents then transcribed into an electronic database.  
There is no external monitor for this study. In accordance with BUMC IRB guidance, an internal 
quality assurance study monitor, if one is needed, will have direct access to the investigator's 
source documentation as needed throughout the study, in order to document compliance with 
the protocol and verify the completeness and accuracy of the data recorded in the official data 
capture forms. The Investigator and their team will cooperate with the study monitor to ensure 
that any problems detected in the course of these monitoring visits are resolved in a reasonable 
period of time. 
7.9 
Data Storage/Security 
Paper subject records will be kept in a locked office and electronic study data will be stored in a 
computer database that will be password protected and kept on the Endocrinology shared drive. 
This storage meets BMC requirements for secure storage of PHI. A password-protected master 
code list will be created that links the subjects study number to the subjects’ identity. The office 


 
 
11 August 2022 Version 11 
31 
will be locked at all times when charts are not in use and will only be accessible to study staff. 
The database master code list will be deleted after completion of the study. 
7.10 
Retention of Records 
The PI will retain all study records including the electronic database files and source documents 
after completion of the study. The database master code list will be kept for 7 years after 
completion of the study, after which it will be deleted, and coded data will be maintained 
indefinitely. Paper files may be stored on-site at BMC or at a secure off-site facility. The study 
team does not need permission from the sponsor to move or destroy the records. 
7.11 
Study Monitoring 
An internal medical monitor (who is NOT a part of the study team) will be appointed by the PI 
who will review for safety (see section 7.12). Apart from this, no external or third party 
monitoring of this study will occur. If an internal audit is requested, the study team will cooperate 
per Section 7.8 Access to Source. 
7.12 
Data Safety Monitoring Plan 
Per the OHRP Guidelines, this study is defined as "greater than minimal risk". Basal/bolus 
insulin regimen is the standard of care for patients with diabetes admitted to the hospital. The 
bolus insulin used routinely in our hospital is Humalog®. In this study, we are evaluating the 
effects of Fiasp® vs NovoLog®, which are being used as bolus insulin instead of Humalog®. 
The risks involved with administration of these two insulins are not different from the risks 
involved with Humalog®. Application of a CGM is a low risk procedure with minimal adverse 
effects. Therefore overall, this study does not have a significantly higher risk compared to the 
standard of care and  we will not establish a Data Safety and Monitoring Board (DSMB). Study 
investigators will meet on a monthly basis to review study data and reported adverse events and 
given the risk level of the study, safety can be adequately monitored by the PI and study team.  
The PI will uphold the following responsibilities: 
• 
An internal medical monitor (who is NOT a part of the study team) will be appointed who 
will review for safety after the enrollment of 10 and 40 patients. Point-of-care and 
continuous glucose monitoring data will be reviewed.  The monitor will review for any 
unacceptably high rates of hyper or hypoglycemia, or excessive need to deviate from the 
study insulin titration protocol, as well as any unexpected and/or severe events that 
warrant a change to the protocol. 
• 
The PI and members of the staff will be responsible for reporting all new clinical 
experiences, exacerbations, and/or deterioration of any existing clinical condition 
occurring after a study subject has entered the study. 
• 
The PI will be responsible for reporting Serious Adverse Events (SAEs) and 
Unanticipated Problems (UPs) to the BMC IRB. Per OHRP Guidelines all UPs should be 
reported to appropriate institutional officials (as required by an institutions written 
reporting procedures), the supporting agency head (or designee), and OHRP within one 
month of the IRB's receipt of the report of the problem from the investigator. 
• 
The PI will be responsible for determining the causality of all AEs/SAEs subject to review 
by the BMC IRB. 


 
 
11 August 2022 Version 11 
32 
• 
The PI and staff will be responsible for follow-up information on all AEs until resolution or 
an appropriate endpoint is reached. 
The PI in concert with BUMC IRB and other study investigators will be responsible for reviewing 
all reports of SAEs that occur in this study and for determining whether any corrective actions 
need to be taken regarding: management decisions of the PI and staff, whether protocol 
violations are congruous with patient welfare taking precedence over protocol, whether there 
are any issues among the research staff that need to be addressed, etc. The study investigators 
will be responsible to determine if the results of its review require a revision/modification of the 
protocol and/or the consent form. An independent reviewer may be considered if there is 
potential for conflict of interest. 
If any expected event listed in the consent form/protocol exceeds what it expected in terms of 
incidence or severity and is thought to be related to study procedures, the study will stop any 
procedures until more can be known about the cause of the excess. 
7.13 
Study Modification 
The study shall be conducted as described in this approved protocol. Deviations or changes to 
the protocol shall be made only after amendment approval/favorable opinion by the IRB, except 
where necessary to eliminate immediate hazard to study participants. Any significant deviation 
will be documented in the study team progress notes. 
If an amendment substantially alters the study design or increases potential risk for study 
participants, the Informed Consent should be revised and submitted to the IRB. Once the IRB 
has approved the revised Informed Consent, all study participants currently enrolled in the study 
must sign the amended consent, and the new consent will be used for all new participants prior 
to enrollment. 
7.14 
Study Discontinuation 
The treatments used in this study fall within accepted clinical practice.  However, if severe 
unanticipated adverse events do occur, then the study will be stopped. 
7.15 
Study Completion 
Data collection is expected to be completed by the end of 2022. When all data and sample 
analyses are completed, the study will be closed with the BUMC IRB per local guidelines. 
7.16 
Conflict of Interest Policy 
Per BMC policy number 09.04.000, all study investigators are required to disclose any 
relationships that may create a potential conflict of interest to BMC using an approved 
institutional Conflicts of Interest form. This occurs at least once per year. Any actual or 
perceived conflicts of interest are managed by the BMC Compliance Department. 
7.17 
Funding Source 
This study is funded by Novo Nordisk, Bagsvaerd, Denmark.   
7.18 
Publication Plan 
We will submit study results for oral presentation at national conferences in Endocrinology as 
well as for publication in a major high impact peer-reviewed journals in that same area after 


 
 
11 August 2022 Version 11 
33 
embargo has been lifted. All presentations and publications will acknowledge the funding 
source. 
 


 
 
11 August 2022 Version 11 
34 
Appendix 1. Insulin initiation protocol 
Initial insulin dose: 
Determine initial TDD using baseline estimate and subtracting of adding for each risk factor: 
Baseline TDD estimate 
Start at 0.5 units/kg/day 
Age >70 years old 
-0.1 unit/kg/day 
If renal insufficiency 
-0.1 unit/kg/day 
If pancreatic deficiency 
-0.1 unit/kg/day 
If HbA1c >10% 
+0.1 unit/kg/day 
FINAL TDD ESTIMATE 
= 
 
Basal dose: Give 50% of dose as insulin glargine every 24 hours. 
Prandial dose:   
Divide the remaining 50% of TDD by 3 and order for each meal.  Round up (for decimals 
0.6 and above) or down (for decimals 0.5 and below) to nearest whole number.  
For Group 1:  Order prandial insulin as NovoLog® 
For Group 2:  Order prandial insulin as Fiasp®  
 
Correction dose: 
Take 1500/TDD = correction factor.  Patients will have correctional scales built for BG 
150-300 mg/dL starting at 150 mg/dL premeal and at 200 mg/dL before bedtime.  Doses 
will start at 2 units.   
For Group 1:  the correction dose will be given as NovoLog® insulin in addition to the 
patients’ scheduled premeal prandial dose. 
For Group 2.  The correction dose will be given as Fiasp® insulin in addition to the 
patients’ scheduled premeal prandial dose. 
At the discretion of the study team, patients with fasting hypoglycemia or judged to be at 
risk for fasting hypoglycemia may have an additional correction scale ordered for 2AM.   
 
BG monitoring:  BG will be measured before each meal using bedside point-of-care 
meters and at bedtime (9 pm) daily.  BG may also be measured if patient experiences 
symptoms of hypoglycemia, to assure correction of hypoglycemia, and if requested by a 
physician.   
 
 


 
 
11 August 2022 Version 11 
35 
Appendix 2. Insulin Titration protocol 
Basal insulin:   
Fasting BG 101-140 mg/dL: continue dose the same 
Fasting hyperglycemia (BG 141-180 mg/dL):  increase dose by 10% 
Fasting hyperglycemia (BG >180):  increase dose by 20%.   
Fasting BG 70-100 mg/dL:  decrease insulin glargine dose by 10% 
If patient develops fasting hypoglycemia (BG 60-69 mg/dL), decrease insulin glargine 
dose by 20% 
If patient develops fasting hypoglycemia (BG 40-59 mg/dL), decrease insulin glargine 
dose by 30% 
If patient develops severe fasting hypoglycemia (BG <40 mg/dL) decrease insulin 
glargine dose by 40% 
 
Correction insulin   
Insulin sensitivity factor will be recalculated daily whenever there is a change in insulin 
dose.   
Prandial insulin:   
Adjust based on BG levels obtained pre-lunch, presupper, and at bedtime as below for 
hyperglycemia: 
If 2 or more BG levels are 170-190 mg/dL without hypoglycemia, increase dose 
by 10% 
If 2 or more BG levels are 191-230 mg/dL without hypoglycemia, increase dose 
by 20% 
If 2 or more BG levels are 231-250 mg/dL without hypoglycemia, increase dose 
by 30% 
If 2 or more BG levels are >250 mg/dL at separate times of a single day, study team to 
stop study titration algorithm, recalculate TDD and adjust insulin based on clinical 
judgement.  
If any BG 70-100 mg/dL, decrease dose by 20% 
If any BG 60-69 mg/dL, decrease dose by 30% 
 
If any BG <60 mg/dL, decrease dose by 50% 
 
 


 
 
11 August 2022 Version 11 
36 
Appendix 3. Prescreening form 
1. Primary language:  English ____  Spanish ____ Other_____ cannot determine ____ 
2. Located on non-intensive care unit: _____ (Y/N) 
3. Age 21-80: _____ (Y/N) 
4. Patient pregnant/breastfeed: ___        __ (Y/N/unknown) 
5. Serum creatinine ≥ 2 mg/dL: _____ (Y/N) 
6. History type 2 diabetes prior to admission: _____ (Y/N) 
7. Outpatient medications: 
a. HbA1c of ≥8% on ≥1 oral or injectable agent:  _____ (Y/N) 
b. Insulin: _____ (Y/N) 
c. 2 oral agents: _____ (Y/N) 
d. Insulin dose >1 unit/kg/day: _____ (Y/N) 
8. Discharge planned within 48 hours: _____ (Y/N) 
9. BMI <45:  _____ (Y/N) 
10. History of type 1 diabetes or LADA (late-onset autoimmune diabetes):  _____ (Y/N) 
11. History of gastroparesis or cirrhosis:  _____ (Y/N) 
12. Currently on glucocorticoids OR plan for treatment with glucocorticoids within the next 72 
hours.(prednisone, dexamethasone, methylprednisolone, hydrocortisone): _____ (Y/N) 
13. Admission diagnosis of diabetic ketoacidosis, hyperglycemic hyperosmolar syndrome, 
solid organ transplantation, or coronary artery bypass surgery: _____ (Y/N) 
14. Receiving tube feeds or total parenteral nutrition: _____ (Y/N) 
15. Expected to be NPO for >24 hours: _____ (Y/N) 
16. Receiving > 1 gram of acetaminophen or hydroxyurea in the hospital: _____ (Y/N) 
17. Using insulin pump or continuous glucose monitoring device in the hospital: _____ (Y/N) 
18. Currently incarcerated: _____ (Y/N) 
19. Allergy to insulin:  _____ (Y/N) 
20. Tested positive for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) OR 
there is an ongoing clinical suspicion for COVID-19 infection in spite of a negative test: 
_______(Y/N) 
 
 


 
 
11 August 2022 Version 11 
37 
Appendix 4. Patient Reported Outcome (PRO) 
Questionnaire 
Instructions:  
A Patient Reported Outcome (PRO) questionnaire is being included in this trial to obtain 
information about the acceptability of wearing a continuous glucose monitoring device while in 
the hospital. 
 
When should the PRO questionnaire be administered? 
At completion of the study.  It takes approximately 5 minutes.   
 
Before giving the PRO questionnaire to the subject 
Fill in the header on each page 
 
Giving the PRO questionnaire to the subject 
-Explain that the questionnaire assesses the subject’s perception of wearing a continuous 
glucose monitoring device in the hospital 
-Explain that the subject should answer the questions him-/herself, without assistance from 
family, friends or medical staff 
-Encourage the subject to answer every question to the best of his/her ability 
-Ask the subject to select only one answer for each question 
-Ask the subject to refrain from writing any extraneous comments in the questionnaire 
-Explain to the subject that the completed questionnaire will be reviewed for any written 
comments that may suggest issues with wearing the continuous glucose monitoring device 
 
Completion of the PRO questionnaire 
-Ensure that a staff member is accessible if questions arises 
-If interpretive questions arise, ask the subject to read the question again and answer based on 
what he/she thinks the question means 
-if the subject accidentally marks an incorrect response, ask him/her to strike it out with a single 
line and mark the correct response instead 
 
After completion of the PRO questionnaire 
-Collect the completed questionnaire from the subject 
-Review them for potential adverse events and document the review on the designated 
signature sheet 
-File the completed questionnaires in the trial file.   
 
 
 
 


 
 
11 August 2022 Version 11 
38 
Questionnaire: 


 
 
11 August 2022 Version 11 
39 
 


 
 
11 August 2022 Version 11 
40 
References 
1.  Swanson CM, Potter DJ, Kongable GL, Cook CB.  Update on inpatient glycemic control in 
hospitals in the United States.  Endocr Pract 2011;17:853-61.   
2.  Moghissi ES, Korytkowski MT, DiNardo M, et al.  American Association of Clinical 
Endocrinologists and American Diabetes Association consensus statement on inpatient 
glycemic control.  Endocr Pract 2009;15:353-369.   
3.  Umpierrez GE, Hellman R, Korytkowski MT, et al.  Endocrine Society.  Management of 
hyperglycemia in hospitalized patients in non-critical care setting:  an Endocrine Society clinical 
practice guideline.  J Clin Endocrinol Metab 2012;97:16-38. 
4.  Wexler DJ, Meigs JB, Cagliero E, Nathan DM, Grant RW.  Prevalence of hyper- and 
hypoglycemia among inpatients with diabetes:  a national survey of 44 U.S. hospitals.  Diabetes 
Care  2007;30:367-9. 
5. Pieber TR, Svehlikova E, Brunner M, et al.  Fast-acting insulin aspart in people with type 2 
diabetes:  Earlier onset and greater initial exposure and glucose-lowering effect compared with 
insulin aspart.  Diabetes Obes Metab 2019;21(9):2068-2075.   
6.  Bode BW, Iotova V, Kovarenko M, et al.  Efficacy and Safety of Fast-acting insulin aspart 
compared with insulin aspart, both in combination with insulin degludec, in children and 
adolescents with type 1 diabetes:  the onset 7 trial.  Diabetes Care 2019;42(7):1255-1262. 
7.  Vellanki P, Rasouli N, Baldwin D et al.  Glycaemic efficacy and safety of linagliptin compared 
to basal-bolus insulin regimen in patients with type 2 diabetes undergoing non-cardiac surgery:  
a multicenter randomized clinical trial.  Diabetes Obes Metab 2019;21:837-43. 
8. Umpierrez GE, Isaacs SD, Bazargan N et al.  Hyperglycemia:  an independent marker of in-
hospital mortality in patients with undiagnosed diabetes.  J Clin Endocrinol Metab 2002;87:978-
82. 
9.  Queale WS, Seidler AJ, Brancati FL. Glycemic control and sliding scale insulin use in 
medical inpatients with diabetes mellitus. Arch Intern Med. 1997;157(5):545-52. 
10.  Umpierrez GE, Smiley D, Jacobs S et al.  Randomized study of basal-bolus insulin therapy 
in in patient management of patients with type 2 diabetes undergoing general surgery (RABBIT 
2 surgery).  Diabetes Care.  2001;34(2):256-61. 
11.  Umpierrez GE, Smiley D, Zisman A et al.  Randomized study of basal-bolus insulin therapy 
in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial).  Diabetes Care.  
2007;30(9):2181-6.    
12. Turchin A, Matheny ME, Subina M et al.  Hypoglycemia and clinical outcomes in patients 
with diabetes hospitalzied in the general ward.  Diabetes Care 2009;32:1153-7/ 
13. Heise T, Pieber TF, Danne T, et al.  A pooled analysis of clinical pharmacology trials 
investigating the pharmacokinetic and pharmacodynamics characteristics of fast-acting insulin 
aspart in adults with type 1 diabetes.  Clin Pharmacokinet 2017;56:551-9.  


 
 
11 August 2022 Version 11 
41 
14.  Burt, MG, Roberts GW, Aguilar-Loza NR, Stranks SN.  Brief report:  comparison of 
continuous glucose monitoring and finger-prick blood glucose levels in hospitalized patients 
administered basal-bolus insulin.  Diabetes Technol Ther 2013;15:241-5.   
15.  Gomez AM, Umpierrez GE, Munoz OM et al.  Continuous glucose monitoring versus 
capillary point-of-care testing for inpatient glycemic control in type 2 diabetes patients 
hospitalized in the general ward and treated with basal bolus insulin regimen.  J Diabetes Sci 
Technol  2015;10:325-9.   
16. Dungan KM, Abdel-Rasoul M, Sagrilla C, Osei K.  Prandial insulin dosing using the 
carbohydrate counting technique in hospitalized patient with type 2 diabetes.  Diabetes Care 
2013;36:3476-82.   
17.  Beck RW, Riddlesworth TD, Ruedy K, et al.  DIAMOND Study Group. Continuous glucose 
monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin 
injections:  a randomized trial.  Ann Intern Med 2017;167;365-74. 
18. Danne T, Nimri R, Battelino T, et al.  International Consensus on the use of continuous 
glucose monitoring.  Diabetes Care  2017;40(12):1631-40.  . 
19. DeVries JH.  Glucose variability:  where it is important and how to measure it.  Diabetes 
2013;62:1405-8. 6.  Dungan KM, Abdel-Rasoul M, Sagrilla C, Osei K.  Prandial insulin dosing 
using the carbohydrate counting technique in hospitalized patient with type 2 diabetes.  
Diabetes Care 2013;36:3476-82.